Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, et al.
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 51-62
Open Access | Times Cited: 216

Showing 1-25 of 216 citing articles:

Metabolically Healthy Obesity
Matthias Blüher
Endocrine Reviews (2020) Vol. 41, Iss. 3
Open Access | Times Cited: 725
Animal models of obesity and diabetes mellitus
Maximilian Kleinert, Christoffer Clemmensen, Susanna M. Hofmann, et al.
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 3, pp. 140-162
Closed Access | Times Cited: 712
The Science of Obesity Management: An Endocrine Society Scientific Statement
George A. Bray, William E. Heisel, Ashkan Afshin, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 2, pp. 79-132
Open Access | Times Cited: 699
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity
Katharina Timper, Jens C. Brüning
Disease Models & Mechanisms (2017) Vol. 10, Iss. 6, pp. 679-689
Open Access | Times Cited: 657
GPCR-Mediated Signaling of Metabolites
Anna Sofie Husted, Mette Trauelsen, Olga Rudenko, et al.
Cell Metabolism (2017) Vol. 25, Iss. 4, pp. 777-796
Open Access | Times Cited: 502
Blaming the Brain for Obesity: Integration of Hedonic and Homeostatic Mechanisms
Hans‐Rudolf Berthoud, Heike Münzberg, Christopher D. Morrison
Gastroenterology (2017) Vol. 152, Iss. 7, pp. 1728-1738
Open Access | Times Cited: 362
The New Biology and Pharmacology of Glucagon
Timo D. Müller, Brian Finan, Christoffer Clemmensen, et al.
Physiological Reviews (2017) Vol. 97, Iss. 2, pp. 721-766
Closed Access | Times Cited: 329
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker, Joel F. Habener, Jens J. Holst
Journal of Clinical Investigation (2017) Vol. 127, Iss. 12, pp. 4217-4227
Open Access | Times Cited: 325
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard, Jonathan D. Douros, M Gabe, et al.
JCI Insight (2020) Vol. 5, Iss. 17
Open Access | Times Cited: 301
Progress and challenges in anti-obesity pharmacotherapy
Daniel H. Bessesen, Luc F. Van Gaal
The Lancet Diabetes & Endocrinology (2017) Vol. 6, Iss. 3, pp. 237-248
Closed Access | Times Cited: 296
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan P. Frías, Edward J. Bastyr, Louis Vignati, et al.
Cell Metabolism (2017) Vol. 26, Iss. 2, pp. 343-352.e2
Open Access | Times Cited: 285
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Gut-Brain Cross-Talk in Metabolic Control
Christoffer Clemmensen, Timo D. Müller, Stephen C. Woods, et al.
Cell (2017) Vol. 168, Iss. 5, pp. 758-774
Open Access | Times Cited: 259
Therapeutic Landscape for NAFLD in 2020
Brent A. Neuschwander‐Tetri
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1984-1998.e3
Closed Access | Times Cited: 168
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller, Christoffer Clemmensen, Brian Finan, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 712-746
Open Access | Times Cited: 163
Metabolic Messengers: glucagon-like peptide 1
Fiona M. Gribble, Frank Reimann
Nature Metabolism (2021) Vol. 3, Iss. 2, pp. 142-148
Closed Access | Times Cited: 143
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 114
Novel therapies with precision mechanisms for type 2 diabetes mellitus
Leigh Perreault, Jay S. Skyler, Julio Rosenstock
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 6, pp. 364-377
Closed Access | Times Cited: 111
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
Fenghui Zhao, Qingtong Zhou, Zhaotong Cong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 94
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 84
Integrative neurocircuits that control metabolism and food intake
Jens C. Brüning, Henning Fenselau
Science (2023) Vol. 381, Iss. 6665
Closed Access | Times Cited: 76
An update on peptide-based therapies for type 2 diabetes and obesity
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2023) Vol. 161, pp. 170939-170939
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top